Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jul 2008

Pitini Vincenzo, Arrigo Carmela, Altavilla Giuseppe

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Erlotinib Hydrochloride
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms, Multiple Primary

Share to Quinazolines

Share to Smoking

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 18640945
DOI: 10.1200/JCO.2008.17.0357

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.PMID 18640945Read ↗

Erlotinib in lung cancer.Semantic proximity Read ↗

Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.Semantic proximity Read ↗

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studySemantic proximity Read ↗

Erlotinib.Semantic proximity Read ↗

Erlotinib as maintenance therapy shows PFS benefit for lung cancer patients with EGFR-mutated tumors.Semantic proximity Read ↗

Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.Semantic proximity Read ↗

Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.Semantic proximity Read ↗

Afatinib Plus Bevacizumab Treatment for a Patient With EGFR S645C-Mutant Non-Small Cell Lung Cancer: A Case Report.Semantic proximity Read ↗

Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.Semantic proximity Read ↗

Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.Semantic proximity Read ↗

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.